In conclusion, by using mass‐spectrometry‐based peptidomics, we show that MASLD is characterised by a previously unreported enhanced oxidised apolipoprotein peptidome, including ApoE and ApoC‐III, which were strongly associated with metabolic impairment and necro‐inflammatory features of MASLD. The gene discussed is APOE; the disease is metabolic dysfunction-associated steatotic liver disease.